Community-wide and School-based Mass Drug Administration (MDA), using praziquantel, given once each year compared to Community-wide and School-based Mass Drug Administration (MDA) given twice each year, six months a part, in gaining and sustaining control of Schistosoma haematobium

ISRCTN ISRCTN32045736
DOI https://doi.org/10.1186/ISRCTN32045736
Secondary identifying numbers N/A
Submission date
14/12/2015
Registration date
16/12/2015
Last edited
20/01/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Schistosomiasis is a long-term (chronic) infection caused by parasites that live in fresh water (for example, rivers and lakes) in tropical and subtropical countries, with over 90% of cases occurring in Africa. It can range from very mild (fever, skin rash, coughing) to more serious (passing blood in diarrhoea or urine, vomiting blood, stomach pains, paralysis of the legs). The World Health Organisation wants to treat 75% of the population who are at risk of a schistosomiasis infection by 2020 and preventive treatment (chemotherapy) will increase massively as a result. In Kenya, the main parasites which cause schistosomiasis (Schistosoma mansoni and Schistosoma haematobium) are common, and so many people suffer from schistosomiasis affecting the urinary and genital organs (intestinal or urogenital schistosomiasis). Before this study, no large-scale preventive chemotherapy programme had been set up in this area. The aim of this study is to use Mass Drug Administration (MDA) in schools and the community in Niger in order to find out the best treatment regimen for the lowest cost.

Who can participate?
First-year adult students in years 1 and 5, and school children aged between 9 and 12 who attend participating schools in Kenya.

What does the study involve?
Each school which is taking part in the study is randomly allocated to one of six groups. In the first group, school-age children and adults are treated with praziquantel once a year for the 4 years of the study. In the second group, school-age children and adults are treated once a year for the first two years of the study and then treated twice a year in years 3 and 4. In the third group, school-age children only are treated once a year for the 4 years of the study. In the fourth group, school-age children only are treated once a year for the first two years of the study and then treated twice a year in years 3 and 4. In the fifth group, school-age children only are treated in year one, on holiday (no treatment) in year 2 of the study and receive treatment once each year in years 3 and 4. In the sixth group, school-age children only are treated once in year 1, on holiday in year 2, and receive 2 treatments every 6 months in years 3 and 4. Throughout the study period, urine samples are taken from participants in order to test for infection.

What are the possible benefits and risks of participating?
There are no risks from the collection of urine for testing for infection. If a person is infected, then they will benefit from receiving treatment. The expected benefit to the village is that the force of transmission will be reduced by the medication provided thus reducing reinfection rates and illness.

Where is the study run from?
RISEAL Niger (Niger)

When is the study starting and how long is it expected to run for?
March 2010 to June 2016

Who is funding the study?
Bill and Melinda Gates Foundation (USA)

Who is the main contact?
Dr Amadou Garba

Contact information

Dr Amadou Garba
Public

RISEAL Niger
333 Avenue of Zarmakoye
Box / BP: 13 724
Niamey
8000
Niger

Study information

Study designCommunity and school-based randomized parallel trial
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Community
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet.
Scientific titleCommunity-wide and school-based annual treatment compared to community-wide and school-based double treatment in controlling Schistosoma haematobium
Study acronymSh Niger
Study objectivesThe implementation of preventive chemotherapy with the anti-schistosomal drug praziquantel in school-aged children (exclusion of children <5 years) and in adults randomized to study arms either receiving treatment twice a year will more cost-effectively gain and sustain the control of prevalence and intensity due to Schistosoma haematobium infection versus treatment once a year with treatment implemented in schools and community venues.
Ethics approval(s)1. National Advisory Committee on Ethics, 22/07/2010, ref: No.011/2014/CCNE
2. Imperial College Research Ethics Committee, 30/07/2010, ref: ICREC_8_2_2
Health condition(s) or problem(s) studiedSchistosomiasis
InterventionIn a first step, in-depth parasitological surveys are carried out to identify 225 schools where the prevalence of S. haematobium (i.e. number of infections) amongst schoolchildren is greater than 10%.

Each school is then randomly allocated into one of six groups, who receive their praciquantel in different treatment regimens. In all groups, the praziquantel is delivered by trained teachers in schools and by drug distributors in the community MDA venues.

Group 1: School-age children and adults in this group are treated with praziquantel once a year for the 4 years of the study.
Group 2: School-age children and adults are treated once a year for the first two years of the study and then treated twice a year in years 3 and 4.
Group 3: School-age children only are treated once a year for all 4 years.
Group 4: School-age children only are treated once a year for the first two years and then twice a year in years 3 and 4.
Group 5: School-age children are treated in year one, on holiday (no treatment) in year 2 of the study and receive treatment once each year in years 3 and 4.
Group 6: School-age children receive treatment once in year 1, on holiday in year 2, and receive 2 treatments every 6 months in years 3 and 4.

Each Year the follow-up includes additional prevalence and intensity testing in the 225 schools, which includes all study Arms. This is collection of urine from each participant and testing that specimen for presence or absence of S. haematobium eggs.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Praziquantel
Primary outcome measureMDA strategy that is able to reduce S. haematobium infection measured by change in prevalence and intensity of Schistosoma haematobium infection in 9- to 12-year-old children is measured at baseline, 1, 2, 3 and 4 years by filtering the urine and preparing slide for microscopic exam. In addition, the urine is observed to see if hematuria visible.
Secondary outcome measures1. Prevalence and intensity of S. haematobium infections in 9- to-12- year-old schoolchildren is measured at baseline, 1, 2, 3 and 4 years using urinalysis
2. Prevalence and intensity of S. haematobium infections in first-year schoolchildren is measured at baseline, 1, 2, 3 and 4 years using urinalysis
3. Identification of S. haematobium risk factors is measured by collecting village inventory data about water, sanitation, hygiene and water body contact at baseline, 1, 2, 3 and 4 years
5. Mapping and prediction of the distribution S. haematobium in Niger is measured by collecting and using GIS coordinates of schools, water bodies and water and sanitation infrastructure at baseline, 1, 2, 3 and 4 years
Overall study start date10/03/2010
Completion date30/06/2016

Eligibility

Participant type(s)Mixed
Age groupMixed
SexBoth
Target number of participants145,000
Key inclusion criteria1. Schoolchildren, either male or female, aged 9-12 years, attending the selected schools (in each study year)
2. First-year students, either male or female, attending the selected schools (in years 1 and 5)
3. Written informed consent signed by parents or legal guardians of the schoolchildren
4. Oral assent from schoolchildren
5. At least one urine sample provided from 9- to 12- years- old children each study year
6. At least one urine sample provided from first-year students and adults in years 1 and 5
Key exclusion criteria1. Children not aged 9-12 years (in years 2, 3 and 4)
2. Adults in Years 2, 3 and 4
2. Children under 9 in Years 2, 3, 4
3. No written informed consent by parents or legal guardians of schoolchildren
4. No oral assent given by schoolchildren
5. No urine sample provided (for 9- to 12-year-old children in each study year; for first-year students and adults in years 1 and 5)
Date of first enrolment01/01/2012
Date of final enrolment31/12/2015

Locations

Countries of recruitment

  • Niger

Study participating centre

RISEAL Niger
333 Avenue of Zarmakoye
Niamey
8000
Niger

Sponsor information

University of Georgia Research Foundation / SCORE
University/education

145Coverdell Center
500 DW Brooks Drive
Athens
30602
United States of America

Phone +1 706 542 1879
Email ccamp@uga.edu
ROR logo "ROR" https://ror.org/00te3t702

Funders

Funder type

Charity

Bill and Melinda Gates Foundation
Government organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Bill & Melinda Gates Foundation, Gates Foundation, BMGF, B&MGF, GF
Location
United States of America

Results and Publications

Intention to publish date29/02/2016
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planPlanned publication of protocol, baseline results and final results in peer reviewed journals.
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol and baseline data 26/05/2016 Yes No
Results article results 01/07/2020 11/02/2021 Yes No
Interim results article Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries 29/09/2017 20/01/2023 Yes No
Other publications Challenges in Protocol Development and Interpretation of the Schistosomiasis Consortium for Operational Research and Evaluation Intervention Studies 12/05/2020 20/01/2023 Yes No

Editorial Notes

20/01/2023: Publication references added.
11/02/2021: Publication reference added.
31/05/2016: Publication reference added.